Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

NCT05824481 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer
Endometrial Adenocarcinoma

Interventions

DRUG: Cadonilimab
DRUG: Lenvatinib

Sponsor

Sun Yat-sen University